Blog Content
How Did Market Research Help Novartis Identify Opportunities in Gene Therapy?
Gene therapy is a highly specialized and evolving field that requires a precise understanding of where treatments can have the most significant impact. Novartis conducted extensive market research to identify conditions where gene therapy could provide a transformative benefit compared to existing treatment options. The company focused on rare genetic disorders with high unmet medical needs, where a one-time treatment could offer a significant quality-of-life improvement. For instance, spinal muscular atrophy (SMA) emerged as a key target based on a combination of epidemiological studies, patient registries, and stakeholder interviews. Novartis analyzed the prevalence of SMA, the limitations of traditional treatments, and the burden of the disease on patients and families. Insights from market research indicated that SMA patients and caregivers were seeking alternatives to lifelong treatments, making gene therapy a compelling option. This research shaped the company’s decision to acquire AveXis, the biotech firm behind Zolgensma, for $8.7 billion in 2018.
Additionally, market research helped Novartis assess the potential for expanding its gene therapy portfolio beyond SMA. The company studied genetic mutations and their impact on disease progression, identifying several rare diseases where gene replacement therapy could provide a breakthrough. These insights guided Novartis in prioritizing research efforts in areas such as hemophilia, sickle cell disease, and inherited retinal disorders.
How Did Novartis Use Market Research to Address Pricing and Reimbursement Challenges?
Gene therapy comes with a high price tag due to its complexity and long-term therapeutic potential. One of the biggest challenges for Novartis was determining how to price Zolgensma effectively while ensuring accessibility for patients. Market research played a crucial role in analyzing pricing models, reimbursement trends, and payer expectations across different regions. Novartis conducted willingness-to-pay studies among insurers, healthcare providers, and government agencies to understand how much the market would support a one-time gene therapy treatment. The research indicated that payers were more receptive to value-based pricing models, where payments were tied to the treatment’s long-term effectiveness. Based on these insights, Novartis introduced an installment-based payment plan, allowing insurers to spread the cost over five years rather than paying upfront.
Further, Novartis used real-world evidence to demonstrate the cost-effectiveness of Zolgensma. Comparative studies showed that a single gene therapy treatment could replace years of expensive supportive care, hospitalizations, and ongoing medication costs. By leveraging these findings, Novartis was able to negotiate favorable reimbursement agreements with multiple healthcare systems, ensuring broader patient access to the treatment.
How Did Market Research Shape Novartis’ Regulatory and Commercial Strategy?
The regulatory landscape for gene therapy is complex, with each country having distinct approval processes and safety requirements. Novartis used market research to navigate these regulatory challenges by analyzing precedent cases, regulatory feedback, and competitor filings. This research helped the company anticipate potential hurdles and align its clinical trial designs with regulatory expectations. For Zolgensma, Novartis focused on gathering patient-reported outcomes and longitudinal health data to strengthen its case for approval. By leveraging insights from SMA patient advocacy groups and physician panels, the company developed a robust dossier that demonstrated both the clinical and economic benefits of the therapy. These research-driven strategies contributed to Zolgensma receiving FDA approval in 2019 and subsequent approvals in Europe, Japan, and other key markets.
Additionally, market research informed Novartis’ go-to-market strategy, ensuring that its sales and distribution channels were optimized for gene therapy delivery. Unlike traditional drugs, gene therapies require specialized infrastructure, including advanced hospital facilities and trained genetic specialists for administration. Novartis conducted surveys with hospitals, clinics, and genetic counselors to identify the best centers for gene therapy rollout. The company then worked with these centers to provide training and logistical support, ensuring seamless patient access.
How Did Market Research Influence Novartis’ Expansion in Gene Therapy?
Beyond SMA, Novartis has continued to use market research to expand its gene therapy portfolio into new therapeutic areas. The company is actively exploring gene therapy applications in conditions such as Duchenne muscular dystrophy (DMD), Parkinson’s disease, and blood disorders. Through patient journey mapping, Novartis has identified critical pain points in these diseases, guiding its R&D investments toward areas where gene therapy can have the highest impact. For example, research in Duchenne muscular dystrophy revealed that existing treatments were only moderately effective and required continuous administration. By analyzing patient data and clinical outcomes, Novartis determined that gene therapy could offer a more durable and potentially curative solution. This insight led the company to invest in new gene therapy candidates targeting DMD and other neuromuscular diseases.
Similarly, in the field of ophthalmology, Novartis used market segmentation analysis to determine which inherited retinal diseases could benefit most from gene therapy. This research-driven approach has allowed the company to prioritize its development pipeline, ensuring that resources are allocated to the most promising gene therapy programs.
What are the Lessons Learned from Novartis’ Market Research Approach?
Novartis’ success in shaping its gene therapy portfolio underscores the importance of data-driven decision-making in pharmaceutical innovation. By continuously monitoring market dynamics, patient needs, and healthcare system challenges, the company has been able to develop transformative gene therapies while ensuring commercial viability.
The company’s approach demonstrates that gene therapy success is not just about scientific breakthroughs, but also about understanding market access barriers, stakeholder concerns, and real-world patient experiences. By integrating market research into every stage of its gene therapy strategy from disease selection and pricing models to regulatory planning and commercial execution Novartis has positioned itself as a global leader in this rapidly evolving field.
Fast Fact
Zolgensma, Novartis’ flagship gene therapy for spinal muscular atrophy, generated over USD 2 billion in revenue in 2022, reflecting the strong market demand for gene therapies and the company’s successful research-driven strategy.
